Clinical trial

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

NCT04839991

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention CB307 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-06-08

PhasePHASE1

Conditions

Advanced and/or Metastatic Solid Tumoursunresolved

Interventions

CB307DRUG

Sponsors & collaborators

Crescendo Biologics Ltd.lead sponsor

Mapped research locations

MadridSpain5 BarcelonaSpain2 LondonUnited Kingdom2 SeattleWashington, United States1 SevilleSpain1 GroningenNetherlands1 RotterdamNetherlands1 UtrechtNetherlands1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04839991 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.